Ian Karp | executive |
John Leonard | executive |
David Lebwohl | executive |
Laura Sepp-Lorenzino | executive |
Glenn Goddard | executive |
Yanan Zhu | analyst |
Maurice Raycroft | analyst |
Troy Langford | analyst |
Luca Issi | analyst |
Harshita Polishetty | analyst |
Konstantinos Biliouris | analyst |
Benazir Ali | analyst |
Lut Ming Cheng | analyst |
Ry Forseth | analyst |
Rick Bienkowski | analyst |
Mehdi Goudarzi | analyst |
Silvan Tuerkcan | analyst |
Timur Ivannikov | analyst |
William Pickering | analyst |
Good morning, and welcome to Intellia Therapeutics First Quarter 2024 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. [Operator Instructions] I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia.